BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21364644)

  • 1. Bcl-2 antagonists and cancer: from the clinic, back to the bench.
    Esposti MD
    Cell Death Dis; 2010 Apr; 1(4):e37. PubMed ID: 21364644
    [No Abstract]   [Full Text] [Related]  

  • 2. Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
    Adams JM; Cory S
    Curr Opin Immunol; 2007 Oct; 19(5):488-96. PubMed ID: 17629468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicking the BH3 domain to kill cancer cells.
    Ni Chonghaile T; Letai A
    Oncogene; 2008 Dec; 27 Suppl 1(0 1):S149-57. PubMed ID: 19641500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
    Aranovich A; Liu Q; Collins T; Geng F; Dixit S; Leber B; Andrews DW
    Mol Cell; 2012 Mar; 45(6):754-63. PubMed ID: 22464442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
    Labi V; Grespi F; Baumgartner F; Villunger A
    Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
    Del Gaizo Moore V; Schlis KD; Sallan SE; Armstrong SA; Letai A
    Blood; 2008 Feb; 111(4):2300-9. PubMed ID: 18056841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
    Stauffer SR
    Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
    Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
    ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEGylated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells.
    Kim SW; Kyung Lee Y; Yeon Lee J; Hee Hong J; Khang D
    Nanotechnology; 2017 Nov; 28(46):465102. PubMed ID: 29053471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Translational Biology: Redefining Druggability of Protein-Protein Interactions.
    Cesa LC
    Chembiochem; 2021 Mar; 22(6):985-987. PubMed ID: 33205588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET.
    Liu Q; Leber B; Andrews DW
    Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-737, proving to be a great tool even before it is proven in the clinic.
    Vaux DL
    Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
    [No Abstract]   [Full Text] [Related]  

  • 15. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
    Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
    Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BH3 mimetics to improve cancer therapy; mechanisms and examples.
    Zhang L; Ming L; Yu J
    Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
    PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.
    Deng J; Carlson N; Takeyama K; Dal Cin P; Shipp M; Letai A
    Cancer Cell; 2007 Aug; 12(2):171-85. PubMed ID: 17692808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutrient Starvation Sensitizes Human Ovarian Cancer SKOV3 Cells to BH3 Mimetic via Modulation of Mitochondrial Dynamics.
    Wang S; Mao Y; Xi S; Wang X; Sun L
    Anat Rec (Hoboken); 2017 Feb; 300(2):326-339. PubMed ID: 27486855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
    Tang Y; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.